MOMA Therapeutics
MOMA Therapeutics is a biotechnology company specializing in the discovery of precision medicines by targeting molecular machines involved in human diseases, having raised $150M in Series B funding.
Series B Funding
MOMA Therapeutics raised $150 million in Series B funding. This financial boost supports the company's ongoing research and development efforts in the field of precision medicines. The substantial funding round reflects investor confidence in MOMA Therapeutics' innovative approach to drug discovery and its potential to bring new therapies to market.
Precision Medicine Focus
MOMA Therapeutics focuses on the discovery of precision medicines by targeting molecular machines that underpin human diseases. The company has identified over 400 molecular machines as potential therapeutic targets. This focus is aimed at creating more effective treatments with the potential to significantly impact patient outcomes by addressing the root causes of diseases at a molecular level.
Innovative Biomechanics Engine
MOMA Therapeutics utilizes a proprietary biomechanics engine that integrates various scientific disciplines, including biochemistry, biophysics, structural biology, computation, chemistry, and functional genomics. This multidisciplinary approach enhances the drug discovery process by providing a comprehensive understanding of molecular machines and their roles in disease, ultimately leading to the identification of effective therapeutic interventions.
Headquarters in Cambridge, MA
MOMA Therapeutics is headquartered at 20 Acorn Park Drive, 6th Floor, Suite 600, Cambridge, MA 02140. The location in Cambridge situates the company within a prominent biotech hub, providing access to a vibrant ecosystem of research institutions, industry leaders, and academic collaborators. This strategic positioning supports MOMA Therapeutics' goals in advancing its drug discovery initiatives.
Target Class-Focused Research Approach
MOMA Therapeutics aims to systematize drug discovery through a target class-focused research approach. By concentrating on specific classes of molecular machines, the company seeks to develop a more organized and efficient pathway for identifying and validating new drug candidates. This methodology emphasizes a structured exploration of potential therapeutic targets to streamline the discovery and development process.
